With targeted cancer drugs, cost vs. benefits gets more complicated

The refusal by NICE on Friday to recommend that the U.K. health system buy Roche's ($RHHBY) melanoma drug Zelboraf illustrates why the debate over expensive end-of-life cancer drugs is not going to die. Story